National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Intuniv® is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6-17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.  It must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.

 

Rapid Review

Commenced Completed Outcome
01/12/2015 18/12/2015 Full Pharmacoeconomic Evaluation Not Recommended